• A New Study Published by Swedish Reseoers Shared Results of the Clinical Trial of A New Drug That Aids Weight Loss In People With Type 2 Diabetes and Obesity.
  • The Medication Is Taken Orally and Has Different Method of Activation Compared To The Popular LPG-1 Drugs.
  • The New Drug Works Through Skeletal Muscle Metabolism, Which the Resear Say Preserves Muscle Mass During Weight Loss.

Millions of People in the United States Have Type 2 diabetes and/or Obesity. Many of the Drugs That Treat Tohe Offen Cause People to Lose Muscle Mass.

Muscle Mass Loss Can causes Loss of Strength and Slow Metabolism. Osteoporosis is also to the concerning the Muscle Massing, Specially in Older People.

Affiliated With The Karolinska Institute and Stockholm University, Both in Sweden, have new drarug that that treats Type 2 Diabetes and Obesity Without Impacting Muscle Mass.

They recently conduct an initial phase 1 clinical trial to determine how Well Humans tolerate the drrug.

The Findings Appear in The Journal Cell.

Ozempic Alternative Aims to Preserve Muscle Mass

LPG-1 Drugs, Including the Popular Semaglutide Medications Ozempic and Wegovy, Work by Reducer Hunger Signals in the Brain and Slowing Gastric Emtying. While these drarugs aid in weight loss, subject Studies have shown that they can reduce lean muscle mass by up to 60%.

Swedish Researchers revealed to New Drug In Tablet Form that Activates Metabolism in the Muscles. In Animal Trials, It Avoided The Muscle Loss Side Effect of LPG-1 Drugs.

Muscle Tissue Is Metabolically Active, So It Burns More Calories at Rest Than Fat. WHEN SUBEONE LOSES MUSCLE DURING WEIGHT LOSS, THIS CAUSES THES RESTING METABOLIC RATE TO SLOW, WHICH CAN MAKE IT TOUCH TO CONTINUE LOSING WEIGHT OR MAINTAIN WEIGHT LOSS.

MUSCLE ALSO HELPS REGULATE BLOOD SUGAR BY ABSORBING GLUCOSE FROM THE BLOODSTREAM. Losing Muscle Can Make Blood Sugar Harder to Control and Worsen Insulin Resistance.

The New Drug is based on Beta-2 Molecule. Beta-2 medications can cause an INCREASED RISK FOR HEART PROBLEMSbut the researchers say the way they reverse the new derrug causes “little or does not increase” in cardiac lesions or hypertrophy.

After behavior trials with the medication, Moved to their first trial involving Humans to see how well they tolerated the medication. The trial consisted of 48 Healthy People and 25 People with Type 2 Diabetes.

Both Groups Took The 2.5 mg Tablet Once Daily for 28 Days. The Scientists Tracked Various Health Metrics from The Participants Including Heart Rate and Blood Pressure.

Humans tolerate The New Drug Well

Both Healthy Participants and Participants With Type 2 Diabetes Were Uble to Tolerate The Drug Well Overall.

The Refectchers Noted That A Side Effect of the Drug Caused “A Mild and Transient Reflection-Driven Increase in Heart Rate” Early in the Trial.

This Side Effect Did Not Persist By Day 28 of the Trial, and The Authors Said There Was No Significant Difference In The Heart Rate Or Blood Pressure Between The Groups.

The Authors Said One Participant had severe adverse Event Related to the Drug. However, The Researchers Noted That It Occurred in “A Patient With Preexisting Cardiac Abnormalities that Resolved Without Complications, and ITS Connection to the Study Drug Rema Rema Uncertain.”

The participants All had plasma Levels consisting with being at a therapeutic level for the medication at the end of the trial. The Researchers Found This Reassuring Since It Showed That Participants were taking the medication as prescribed and validated the Heart Metrics remembered.

Since this phase of the trial was Successful, The Next Step is a longer clinical phase 2 trial. This Trial Will See the Drug Affects People With Type 2 Diabetes and/Or Obesity in Terms of Muscle Mass, Glucose Levels, and insulin sensitivity.

Experimental Weight -los Drug Shows Promise

Mir Ali, MD, A Board Certified General Surgeon, Bariatric arguon, and Medical Director of Memorialcare Surgical Weight Loss Center, Spoke With Medical News Today about the trial.

“This sems to be a promising drag could be a potential Weight Loss and Diabetes Medication,” Said Ali, Who Was Not Involved in This Study.

Ali Noted That a Clinical Trial is Needed Comparing the Medication to the LPG-1 Drugs Available. “OFTEN, The Real-World Results Vary Significantly From Initial Studies,” He Poleded out.

The Doctor Also Touched on Why a Weight Loss Drug That Does Not Cause Muscle Loss Is So Important:

“Preservating Muscle Mass Is Important in Any Kind of Weight Loss; The Goal is to Lise Fat and Not Muscle. The Load Leads to Weakness and A Slow Metabolic Rate; More Muscle Means More Caliers are calories are Burned, Even at Rest

Maria Knöbel, MBBS, Medical Director of Medical Cert UK, Similarly Who Was Not Involved in the Recentch, Also Spoke With MNT about the trial results.

Knöbel Said That, with her patients Who Lose Weight, She has noticed that “A Great Decline in musculaure Levels Occurs, and This Increases Their Insulin Resistance and Further Complicates Their.

“The trial of this drarug is promising since it is a solution to this issue since it provides a means of losing fat Without losing muscles,” She notted. “The Saving of Muscle Mass With Weight Loss In these Patients Would Be Instrumental to the Long-Term Control of Glucose and Would to Better Outcomes Concerning Their Diabetes Treatment.”